ABSORBABLE IRON-BASED IMPLANTABLE DEVICE
An absorbable iron-based implantable device, including an iron-based substrate and a hydrophobically-modified high polysaccharide attached to the iron-based substrate. The solubility of the modified high polysaccharide in an organic solvent is increased when hydrophobically modified, this allows great film formation on the iron-based substrate when a coating method such as spraying or dip coating is employed for the preparation of a coating, thus allowing an increased amount of the modified high polysaccharide to be attached to the iron-based substrate. When the absorbable iron-based implantable device is implanted into the body, the degradation of the modified high polysaccharide produces an increased amount of degradation product that reacts with a corrosion product of the iron-based substrate to produce a water-soluble polysaccharide-iron complex, thus reducing the production of an insoluble solid corrosion product.
1 - 13 . (canceled)
14 . An absorbable iron-based implantable device, comprising:
an iron-based substrate; and
a modified high polysaccharide attached to the iron-based substrate, wherein the modified high polysaccharide is a hydrophobically modified high polysaccharide.
15 . The absorbable iron-based implantable device of claim 14 , wherein the modified high polysaccharide is formed by grafting a hydrophobic group to a high polysaccharide.
16 . The absorbable iron-based implantable device of claim 15 , wherein the hydrophobic group is a hydrocarbyl group having 8-24 carbon atoms; or the hydrophobic group is a hydrocarbyl group containing at least one of aryl, hydroxyl, carboxyl, an ester group, an isocyanate group, an ether group, amine group and acyl or a hydrocarbyl group containing a double bond; or the hydrophobic group is at least one selected from polyoxypropenyl, a long chain perfluoroalkyl and a polysiloxane group.
17 . The absorbable iron-based implantable device of claim 15 , wherein the hydrophobic group reacts with hydroxyl, carboxyl, or the amino group of the high polysaccharide to graft to the high polysaccharide.
18 . The absorbable iron-based implantable device of claim 14 , wherein the solubility of the modified high polysaccharide in water at 37° C. is less than or equal to 0.01 g, and the solubility of the modified high polysaccharide in an organic solvent is greater than or equal to 0.1 g.
19 . The absorbable iron-based implantable device of claim 14 , wherein the degradation period of the modified high polysaccharide in vivo is greater than 3 months.
20 . The absorbable iron-based implantable device of claim 14 , wherein a degradation product of the modified high polysaccharide in vivo reacts with the iron-based substrate to form a polysaccharide-iron complex having a solubility in a physiological solution of not less than 1 g.
21 . The absorbable iron-based implantable device of claim 14 , wherein the high polysaccharide is at least one selected from glucan, chitosan, plant polysaccharides, starch, dextrin, cellulose, glycogen, chitin, tunicin, inulin, agar, gum arabic, hyaluronic acid, gellan gum, curdlan, xanthan gum, pectin, konjac glucomannan, gum arabic, lichenin, alginate, spirulina polysaccharide, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin and heparan sulfate.
22 . The absorbable iron-based implantable device of claim 21 , wherein the plant polysaccharide is ginseng polysaccharide, astragalus polysaccharide, angelica polysaccharide, lycium barbarum polysaccharide or capsicum polysaccharide.
23 . The absorbable iron-based implantable device of claim 14 , wherein the modified high polysaccharide is located on a surface of the iron-based substrate, or the modified high polysaccharide is filled inside of the iron-based substrate.
24 . The absorbable iron-based implantable device of claim 14 , wherein the absorbable iron-based implantable device further comprises a degradable polymer layer disposed on the iron-based substrate, and the degradable polymer layer is made of at least one material selected from a degradable polyester and a degradable polyanhydride, wherein the degradable polyester is any one selected from the group consisting of polylactic acid, polyglycolic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyhydroxyalkanoates, polyacrylates, polysuccinates, poly(β-hydroxybutyrate) and polyethylene adipate; or the degradable polyester is a physical blend of at least two selected from the group consisting of polylactic acid, polyglycolic acid, polysuccinate, poly(β-hydroxybutyrate), polycaprolactone, polyethylene adipate, poly(lactic-co-glycolic acid) and polyhydroxybutyrate-valerate copolymer; or the degradable polyester is any one copolymer formed by copolymerization of at least two selected from monomers forming polylactic acid, polyglycolic acid, polysuccinate, poly(β-hydroxybutyrate), polycaprolactone, polyethylene adipate, poly(lactic-co-glycolic acid) and polyhydroxybutyrate-valerate copolymer; or the degradable polyanhydride is at least one selected from the group consisting of poly(1,3-bis(p-carboxyphenoxy) propane-sebacic acid), poly(erucic acid dimer-sebacic acid) and poly(fumaric acid-sebacic acid); or the degradable polyanhydride is any one copolymer formed by copolymerization of at least two selected from monomers forming poly(1,3-bis(p-carboxyphenoxy) propane-sebacic acid), poly(erucic acid dimer-sebacic acid) and poly(fumaric acid-sebacic acid);
or, the material of the degradable polymer layer is a copolymer formed by copolymerization of at least two monomers forming the degradable polyester and the degradable polyanhydride.
25 . The absorbable iron-based implantable device of claim 24 , wherein the degradable polymeric layer further comprises an active drug which is at least one selected from the group consisting of antiangiogenic drugs, antiplatelet drugs, antithrombotic drugs, anti-inflammatory drugs, and anti-sensitizing drugs.
26 . The absorbable iron-based implantable device of claim 25 , wherein the antiangiogenic drug is selected from at least one of paclitaxel, rapamycin, and rapamycin derivatives; the antiplatelet drug is cilostazol; the antithrombotic drug is heparin; the anti-inflammatory drug is dexamethasone; and the anti-sensitizing drug is at least one selected from calcium gluconate, chlorphenamine, and cortisone.